ARMATA PHARMACEUTICALS, INC.— Sankey Diagram

Quarterly mode · period ending 2020-06-30 · SEC EDGAR

ComparingFY2020 (Q4) vs FY2019 (Q4)
Revenue
$31K
Gross Profit
$31K
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2020 (Q4)
Revenue$31K
COGS$0
Gross Profit$31K
R&D$3M
SG&A$0
D&A$300K
Other OpEx$0
Operating Income$0
Interest Exp.$0
Other Non-Op$0
Pretax Income$0
Tax$0
Net Income$0

QuarterCharts · SEC EDGAR data · ARMP · Comparing FY2020 (Q4) vs FY2019 (Q4)